乐普生物
LEPU BIOPHARMA

LEPU BIOPHARMA CO., LTD.
樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR

Lepu Biopharma Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that, on July 15, 2026, 2026, the supervisory board (the "**Supervisory Board**") of the Company received a written resignation letter from Ms. Zhao Lixuan (趙力萱) ("**Ms. Zhao**"), an employee representative supervisor of the Company, who resigned as an employee representative supervisor of the Company due to pursuit of other professional engagements. Her resignation took effect from July 15, 2026 onwards.

Ms. Zhao confirmed that she has no disagreement with the board of directors (the "**Board**") of the Company and the Supervisory Board during her term of office and there is no other matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company. The Company would like to express its gratitude to Ms. Zhao for her contribution to the Company during her tenure as an employee representative supervisor of the Company.

Ms. Ren Fangyuan (任方源) ("**Ms. Ren**") was elected as an employee representative supervisor of the Company upon the election at the employee representatives' meeting (the "**Employee Representatives' Meeting**") of the Company, with effect from July 15, 2026 to the expiration of the term of the current session of the Supervisory Board.

Details of Ms. Ren which are required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), are set out as follows:

Ms. Ren Fangyuan (任方源), aged 25, is an Employee Representative Supervisor of the Company. Ms. Ren joined the Group in August 2025 and currently serves as an officer in our Securities Business Department. Ms. Ren obtained a Bachelor's degree in Finance from Concordia University in May 2023 and a Master's degree in Finance from the University of Rochester in December 2024.

The Company has entered into a service contract with Ms. Ren and the term of office of Ms. Ren as employee representative Supervisor will be from the date of appointment and ending on the expiration of the term of the current session of the Supervisory Board.

Saved as disclosed herein, as at the date of this announcement, Ms. Ren (i) has not held any other major positions within the Group and has not held any directorships in any other listed companies in Hong Kong or overseas in the last three years; (ii) does not have any interest or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations required to be disclosed pursuant to Part XV of the SFO; and (iii) has no relationships with any other Directors, Supervisors, members of senior management or substantial Shareholders of the Company. Save as disclosed herein, there is no other information required to be disclosed pursuant to Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Listing Rules and there are no other matters that need to be brought to the attention of the Shareholders.

By order of the Board
Lepu Biopharma Co., Ltd.
Dr. Pu Zhongjie
Chairman of the Board and Executive Director

Shanghai, the PRC, July 15, 2026

As at the date of this announcement, the Board comprises Dr. Pu Zhongjie (chairman) and Dr. Sui Ziye (chief executive officer) as executive Directors; Ms. Pu Jue and Ms. Qin Yiran as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.